MassDevice

Boston Scientific reports positive findings for Ekos endovascular system in pulmonary embolism

Boston Scientific (NYSE:BSX) announced positive data from a randomized clinical trial evaluating its EKOS endovascular system.
Endovascular Today

HI-PEITHO: Boston Scientific’s Ekos System Superior to Anticoagulation Alone in Acute Intermediate-Risk PE

Boston Scientific Corporation announced that the HI-PEITHO global randomized clinical trial evaluating the use of the Ekos endova ...
MassDevice

The biggest cardiology tech stories out of ACC 2026

The biggest names in cardiology tech gathered in New Orleans for the American College of Cardiology (ACC) Scientific Sessions ...
KAKE.com

HI-PEITHO trial demonstrates Boston Scientific EKOS™ Endovascular System is superior to standard of care for treatment of acute pulmonary embolism

Global randomized trial demonstrated statistically significant reduction in clinical event rates in patients with intermediate-risk PE when treated with the EKOS device plus anticoagulation vs.
Seeking Alpha

REAL-PE Study Demonstrates Statistically Significant Lower Major Bleeding Rates with the EKOS™ Endovascular System Compared to Mechanical Thrombectomy Device for Treatment of ...

Analysis is first to compare health system-based electronic health record data for treatment of pulmonary embolism with interventional devices MARLBOROUGH, Mass., Oct. 24, 2023 /PRNewswire/ -- Data ...
Medical Device Network on MSN

Boston Scientific presents Watchman FLX and EKOS endovascular system data

Boston presented the pair of trial readouts at the 2026 American College of Cardiology (ACC) conference in New Orleans.
Yahoo Finance

HI-PEITHO trial demonstrates Boston Scientific EKOS™ Endovascular System is superior to standard of care for treatment of acute pulmonary embolism

PE is a blood clot that causes a blockage in one or more pulmonary arteries that bring blood to the lungs, and is the third leading cause of cardiovascular mortality. 1 Current medical guidelines for ...